Nanovi

Nanovi is a Copenhagen-based medical device company focused on precision oncology through its proprietary liquid fiducial markers. Its lead product, BioXmark®, is a CE-marked liquid marker designed to enhance target visibility for high-precision radiation therapy in humans, while PetXmark™ serves the veterinary oncology market. The company was acquired by CQ Medical in October 2023, signaling a successful exit and integration into a larger commercial entity. Nanovi's technology platform, developed in collaboration with DTU, addresses a critical need for flexible and accurate soft tissue marking across cancer types.

Patented 'carbo-gel' biomaterial platform for creating injectable liquid fiducial markers that solidify in situ, providing multi-modality imaging visibility for precise tumor targeting in radiation therapy and surgery.

Nanovi competed in the fiducial markers segment against large medtech companies offering traditional solid markers (e.g., gold seeds). Its liquid technology differentiated on conformability, reduced migration risk, and multi-modality visibility. It also faced competition from other tumor localization methods like electromagnetic transponders and MRI-guided systems.